Catalent
CTLT
$55.92
Share price
0.22%
Change (1 day)
19.11%
Change (1 year)
Categories
Catalent is an American pharmaceutical contract research and development company.
Catalent (CTLT) - Net assets
Net assets on the balance sheet as of December 2023 : $3.68 B
According to Catalent's latest financial reports the company has $3.68 B in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Catalent - Net assets on balance sheet (from 2013 to 2023)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2023-06-30 | $4.61 B | -3.43% |
| 2022-06-30 | $4.77 B | 11.72% |
| 2021-06-30 | $4.27 B | 21.91% |
| 2020-06-30 | $3.50 B | 53.22% |
| 2019-06-30 | $2.28 B | 110.56% |
| 2018-06-30 | $1.08 B | 50.2% |
| 2017-06-30 | $0.72 B | 13.78% |
| 2016-06-30 | $0.63 B | 0.3% |
| 2015-06-30 | $0.63 B | -270.52% |
| 2014-06-30 | $-0.38 B | -9.38% |
| 2013-06-30 | $-0.42 B | 16.99% |
| 2012-06-30 | $-0.36 B |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Supernus Pharmaceuticals
SUPN | $0.92 B | -75.01% | 🇺🇸 USA |
 Jazz Pharmaceuticals JAZZ | $3.73 B | 1.36% | 🇮🇪 Ireland |
 Aerie Pharmaceuticals AERI | -$0.17 B | -104.45% | 🇺🇸 USA |
 Intercept Pharmaceuticals
ICPT | $71.84 M | -98.05% | 🇺🇸 USA |